Meeting Coverage:

American Academy of Ophthalmology

AAO: 2020

A Research Analysis of Brolucizumab in the Real World

Show Description +

Michael S. Ip, MD, discusses the rate and risk stratification of the safety profile of brolucizumab-dbll (Beovu, Novartis) in the treatment of wet age-related macular degeneration (AMD), with reference to the HAWK and HARRIER phase 3 clinical trials. Dr. Ip talks about the retrospective analysis he and his colleagues conducted of real-world patients who received brolucizumab for the treatment of wet AMD and shares some interesting points from their analysis.

Posted: 11/05/2020

Up Next


Entrustable Physician Activities

Thomas A. Oetting, MD

Deep Learning: OCT and Disease Prediction

Tien Y. Wong, MD, MBBS, MPH, FRCS(Ed), Phd

Genetic Targeting & Glaucoma

Milica Margeta, MD

Does This New IOL Deliver?

Devesh K. Varma, MD

A Research Analysis of Brolucizumab in the Real World

Michael S. Ip, MD, discusses the rate and risk stratification of the safety profile of brolucizumab-dbll (Beovu, Novartis) in the treatment of wet age-related macular degeneration (AMD), with reference to the HAWK and HARRIER phase 3 clinical trials. Dr. Ip talks about the retrospective analysis he and his colleagues conducted of real-world patients who received brolucizumab for the treatment of wet AMD and shares some interesting points from their analysis.

Posted: 11/05/2020


Please log in to leave a comment.

More From AAO: 2020 Coverage